We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Improving the regulation of medical cannabis in Canada to better serve pediatric patients.
- Authors
Huntsman, Richard J.; Kelly, Lauren E.; Alcorn, Jane; Appendino, Juan Pablo; Bélanger, Richard E.; Crooks, Bruce; Finkelstein, Yaron; Gilpin, Andrea; Lewis, Evan; Litalien, Catherine; Jacobs, Julia; Moore-Hepburn, Charlotte; Oberlander, Timothy; Rassekh, S. Rod; Repetski, Alexander E.; Rieder, Michael J.; Shackelford, Alan; Siden, Hal; Szafron, Michael; 't Jong, Geert W.
- Abstract
[12] Requiring GMP certification for medical cannabis products could, however, result in a 2-tier regulatory system (with GPP and GMP certification required for recreational and medical cannabis products, respectively), and some producers may elect to exit the medical cannabis market. Health Canada also maintains a system for reporting adverse events associated with cannabis products on its Canada Vigilance website.[9] Licensed cannabis producers are required to report serious adverse events associated with the use of their products, but it is not mandatory for health care providers to do so. Children with chronic debilitating illness and pain are increasingly using cannabis for medical purposes, particularly when conventional treatment options have limited benefit or substantial adverse effects.
- Subjects
CANADA; MEDICAL marijuana; MEDICAL laws; CHILD patients; EVIDENCE-based management; CHILDREN with autism spectrum disorders; MEDICAL personnel; WARNING labels; HEALTH policy; GOVERNMENT regulation; HYDROCARBONS; MEDICAL protocols; THERAPEUTICS
- Publication
Canadian Medical Association Journal (CMAJ), 2021, Vol 193, Issue 41, pE1596
- Publication type
journal article
- DOI
10.1503/cmaj.202169